ORIC Pharmaceuticals, Inc. (ORIC)
ORICNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$9.37
+0.6900 (+7.95%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $956.71m
- P/E
- –
- EPS, last 4 quarters
- $-1.35
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.23 to $14.68
- Average volume
- 1.67m
- Previous close
- $8.68
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $22.38, +138.8% from here
Earnings
next estimate $-0.4100Next report Nov 12, 2026
Sep 2025
+19.5%
Dec 2025
+11.8%
Mar 2026
-9.7%
Jun 2026
-5.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$36.67m | -$34.55m | -$39.62m | -$45.30m |
| Net income | -$32.59m | -$30.50m | -$35.77m | -$41.49m |
News
8 latest- Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer StudyMarketBeat · Oct 23, 2026
- ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer Data RTTNews · Oct 23, 2026
- ORIC Pharmaceuticals, Inc. Announces Phase 1b Enozertinib Data and Plans for Phase 3 Redwood-1 Trial in 1H 2027Fintel · Oct 23, 2026
- BTIG Initiates Coverage of ORIC Pharmaceuticals at BuyFintel · Sep 23, 2026
- ORIC Q2 Loss Widens As Phase 3 Trial For Prostate Cancer Progresses; Stock Down RTTNews · Aug 4, 2026
- Tuesday's ETF Movers: XSD, XBIBNK Invest · Jun 2, 2026
- ORIC Reports Q1 Results; Highlights Progressing Trials For Cancer Therapies RTTNews · May 5, 2026
- Stocks Settle Higher on Hopes for Conclusion to Iran WarBarchart · Apr 2, 2026
The company
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer . ORIC's clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- oricpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.